Tenderwize
Retour à la recherche

Open House Drug Discount Agreements Diclofenac, ATC D11AX18

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Feb 03, 2028 · 523 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Diclofenac, ATC D11AX18

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

Open-house model does not guarantee any volume; revenue depends on patients using the discount agreement.

Strict document requirements (two paper originals or qualified electronic signature) can cause delays if not followed p...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive discount agreements for Diclofenac (ATC D11AX18) with AOK Bayern
  • Open-house model: all eligible pharmaceutical companies can join without selection
Afficher le résumé complet

This is an open-house model (not a traditional procurement) by AOK Bayern for non-exclusive discount agreements on Diclofenac (ATC D11AX18) under §130a Abs. 8 SGB V. Any eligible pharmaceutical company can conclude an identical, non-negotiable contract. Contracts run from April 1, 2026 to March 31, 2028, with enrollment possible at any time until February 3, 2028. No estimated value is provided.

Risques

Open-house model does not guarantee any volume; revenue depends on patients using the discount agreement.

Strict document requirements (two paper originals or qualified electronic signature) can cause delays if not followed p...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company

Administrative

  • Submit signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Submit signed contract and annex listing covered medicines

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open House Drug Discount Agreements Diclofenac, ATC D11AX18

Non-exclusive discount agreements for Diclofenac (ATC D11AX18) with AOK Bayern. All pharmaceutical companies meeting eligibility can join. Contract duration: April 1, 2026 to March 31, 2028.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Mar 2026 - Mar 2028

Catégorie

Pharmaceutical products

Détails de la procédure

Date de publication
15 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
108714-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30